Showing papers by "Shin-ichiro Fujiwara published in 2018"
TL;DR: Myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement are hematopoietic stem cell disorders with a poor prognosis, but no established standard therapy.
Abstract: Objective Myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement are hematopoietic stem cell disorders with a poor prognosis, but no established standard therapy. Methods We experienced a patient with T-lymphoblastic lymphoma (LBL) associated with FGFR1 rearrangement who underwent cord blood transplantation, but died of pulmonary complication. We collected the clinical data of patients with FGFR1 rearrangement from the medical literature and analyzed 45 patients, including our patient. Results The primary diagnoses were myeloproliferative neoplasm (MPN) or myelodysplastic syndromes (MDS) in 14 and acute leukemia or LBL in 31. In MPN and MDS patients, the cumulative incidence of transformation to blast phase (BP) at 12 months was 46.2%. The 1-year overall survival (OS) from diagnosis in all cases was 43.1%. With regard to the impact of treatment response on survival, the achievement of complete response with a landmark at 2 months after diagnosis of BP was associated with a superior OS (40.0% vs. 26.0% P = 0.011 for 1-year OS from BP). Allogeneic hematopoietic stem cell transplantation (HSCT) was performed in 13 patients, and the 1-year OS from allogeneic HSCT was 61.5%. The hazard ratio for mortality was 0.34 (95% CI, 0.08-1.51, P = 0.15) for allogeneic HSCT treated as a time-dependent covariate, which suggests that allogeneic HSCT may confer a clinical benefit. Conclusion The further accumulation of clinical data is needed to determine the optimal therapeutic approach for these neoplasms.
23 citations
TL;DR: It is demonstrated that host hematopoietic, but not nonhematopoetic, APCs play a critical role in the development of CD4+ T cell-mediated GVHD, and this findings provide a better understanding of the immunobiology of humanized mice and support theDevelopment of novel options for the prevention and treatment for GV HD.
22 citations
TL;DR: Sequential monitoring of the WT1 mRNA is of value for the early detection of hematologic relapse in patients with AML in remission after chemotherapy or stem cell transplantation.
Abstract: Background Wilms' tumor 1 (WT1) mRNA expression is a universal marker of minimal residual disease in patients with acute myeloid leukemia (AML). The aim of this retrospective study was to evaluate the ability of serial measurement of peripheral blood WT1 mRNA levels to predict relapse in patients with AML in remission. Patients and Methods From April 2012 to May 2015, 131 patients with AML were admitted to our hospital. Among them, 55 were examined for WT1 mRNA at least 3 times during complete remission to assess minimal residual disease, and thus were included in the following analyses. Results With a median follow-up duration of 921 days, 34 remained in remission, but their WT1 values frequently increased to 100 copies/μg RNA. Therefore, we focused on the 40 posttreatment observation periods of 37 patients who experienced high WT1 values (defined as those above 100 copies/μg RNA) at least once after they achieved remission. The cumulative incidence of hematologic relapse was 75.8% at 6 months in 26 patients with 2 consecutive high WT1 values, whereas just 1 of the 14 patients with only 1 high WT1 value relapsed (P Conclusion Sequential monitoring of the WT1 mRNA is of value for the early detection of hematologic relapse in patients with AML in remission after chemotherapy or stem cell transplantation.
14 citations
Jichi Medical University1, Akita University2, Tokai University3, St. Marianna University School of Medicine4, National Defense Medical College5, Jikei University School of Medicine6, Nagasaki University7, Gulf Coast Regional Blood Center8, Tokyo Medical University9, University of Tsukuba10, Gunma University11, Osaka City University12, Memorial Hospital of South Bend13, Hamamatsu University School of Medicine14
TL;DR: This study demonstrated that released washed PCs were effective and safe in patients with a history of transfusion reactions and further prospective studies on efficacy and safety together with cost-benefit analysis in RWPCs are needed.
10 citations
TL;DR: A patient who developed false-positive BDG elevation during the administration of PCG for osteomyelitis due to Streptococcus pneumoniae infection is experienced, and elevated BDG levels should be interpreted with caution, as they may be false- positive results.
10 citations
TL;DR: The data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT, however, further studies are warranted to confirm this observation.
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML hav...
8 citations
TL;DR: This is the first report to suggest that 2G-TKIs may have direct or indirect effects on FL, and a 50-year-old man who was diagnosed with CML in the chronic phase and treated with imatinib achieved a complete response to FL without antilymphoma treatment.
Abstract: Tyrosine kinase inhibitors (TKIs) are standard therapy for chronic myeloid leukemia (CML). However, the effects of these agents on mature B cell lymphoma are not well known. We describe a 50-year-old man who was diagnosed with CML in the chronic phase and treated with imatinib. After 3 years of imatinib therapy that achieved a complete cytogenetic response of CML, he developed Philadelphia-negative follicular lymphoma (FL). Rituximab monotherapy induced a partial response of FL, and he subsequently achieved a major molecular response (MMR) of CML. Three years later, however, the MMR was lost, followed by the progression of FL. Imatinib was switched to nilotinib for the treatment of CML, while we chose watchful waiting for FL. He achieved MMR again under treatment with nilotinib for 8 months including one month of substitutional use of dasatinib due to adverse events, but thereafter nilotinib was switched to bosutinib due to hyperbilirubinemia. With the administration of second-generation TKIs (2G-TKIs) for a total of 18 months, he achieved a complete response to FL without antilymphoma treatment. This is the first report to suggest that 2G-TKIs may have direct or indirect effects on FL.
6 citations
TL;DR: This patient is a unique case of leukemic DH-FL with t(8;14;18) that remained in FL even at a second relapse, not only at presentation but even after aSecond relapse.
2 citations
TL;DR: In conclusion, ivBU1 can be safely administered with clinical outcomes similar to those with ivBU4, and is routinely used in a conditioning regimen in adult patients with myeloid malignancy who undergo allogeneic hematopoietic stem cell transplantation.